Skip to content

Combination of Platelets Rich Plasma and Hyaluronic is an Effective Tool for Treatment of Knee Osteoarthritis

Combination of Platelets Rich Plasma and Hyaluronic is an Effective Tool for Treatment of Knee Osteoarthritis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07089446
Enrollment
60
Registered
2025-07-28
Start date
2022-09-21
Completion date
2025-06-15
Last updated
2025-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthristis

Keywords

Hyaluronic acid, osteoarthritis, pain, disability

Brief summary

The purpose of the study is to determine the effects of HA, PRP and the combination of HA and PRP in reducing pain and improving functional disability in patients with knee osteoarthritis.

Detailed description

To determine the effects of combination of platelet rich plasma (PRP) and hyaluronic acid and the PRP or HA alone in reducing pain and increasing range of motion among individuals with knee osteoarthritis.

Interventions

DRUGHyaluronic Acid (HA)

Hyaluronic Acid

DRUGPlatelet Rich Plasma

Platelet rich plasma

Hyaluronic Acid and Platelet rich plasma

Sponsors

University of Karachi
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Single blinded study, only the assessor was kept blinded

Intervention model description

Participants were randomly divided into three groups. Twenty cases (Group A) were injected with HA, 20 (Group B) had PRP, and the remaining 20 (Group C) received a combination of HA and PRP

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* grade II-III according to the Kellgren-Lawrence classification), * pain or functional limitations in patients' activity of daily living before the treatment, * age between 40 and 70 years of age, and the absence of clinical or imaging signs of articular instability.

Exclusion criteria

* includes known hypersensitivity to hyaluronic acid, * pregnancy and lactation, a BMI greater than 40 kg/m2, * chronic administration of anticoagulant drugs or a history of coagulopathies, * neoplastic lesions, and knee or kidney failures

Design outcomes

Primary

MeasureTime frameDescription
visual analogue scaleRecorded before the treatment and repeated within 3 and 6 months after the treatment.It is a straight line, 100 millimeters long line, one end of the line means not at all or none and the other end means the worst possible or extremely.

Secondary

MeasureTime frameDescription
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Recorded before the treatment and repeated within 3 and 6 months after the treatment.It s a questionnaire used to assess pain, stiffness, and physical function in individuals with osteoarthritis, particularly of the knee. It is a self-administered, multidimensional tool that evaluates these three dimensions through a series of questions, typically on a Likert scale.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026